Wednesday, November 6, 2013

News from The American College of Rheumatology 2013 Meeting

Today, I would like to share an exciting survey with you that was presented at the annual by CreakyJoints and Janssen at the American College of Rheumatology's annual meeting.

CreakyJoints is an Arthritis Support Community for people living with RA, OsteoArthritis, Rheumatic Diseases as well as their caregivers. 

As a leader in Immunology, Janssen is committed to the Rheumatology community focusing on providing therapeutic options and support to patients living with Chronic Rheumatic conditions.

Highlights of the survey shows how important communication with your Rheumatologist is,
It also shows that patients are open to more than one type of therapy. I will provide the info-graphic and the full release below.

 Here is a link to a brief video presentation from Creaky Joints Co-Founder Seth Ginsberg:

I hope you will find it as interesting as I do, it shows we are heading in the right direction and I hope you will share it.


More Patients Expressed a Preference for Infusion Modes of Administration than Rheumatologists Believed

SAN DIEGO, October 28, 2013 – Data presented by Janssen Scientific Affairs, LLC, in collaboration with the patient advocacy organization CreakyJoints, reveal that more than half of surveyed patients with rheumatoid arthritis (RA) were open to both subcutaneous (SQ) and intravenous (IV) biologic therapy, and that more patients preferred IV biologic therapy given by a healthcare professional than surveyed rheumatologists believed. The data are being presented at the 2013 Annual Meeting of the American College of Rheumatology (ACR).

Approximately 1.3 million people in the United States are living with RA,[i] a chronic, systemic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability.[ii] Current guidelines for the treatment of RA recommend that patients who are not adequately responding to treatment with disease-modifying antirheumatic drugs (DMARDs), most often methotrexate, initiate treatment with biologic therapy, a genetically engineered medication that can interfere with inflammatory substances in the body.[iii] Biologics are administered either by subcutaneous injection, by a healthcare professional or the patient, or by intravenous infusion at a hospital or certified infusion center.[iv] 

“The results of this study emphasize the importance of effective communication between patients and providers. Patients should be open with their rheumatologist about their disease and treatment to ensure they are actively contributing to their treatment plan,” said Seth Ginsberg, co-founder and president of CreakyJoints.

The purpose of the study was to explore openness to and preference for IV and SQ formulations of biologic therapy among adult patients diagnosed with RA and currently treated by a rheumatologist with DMARDs prior to biologic initiation from the perspectives of both patients and prescribers. A total of 243 patients were recruited through CreakyJoints (n=101) and a consumer panel (n=142), while 103 prescribers were recruited through a physician panel to compare patient perspectives to rheumatologists’ perspectives. The study found that overall, 53 percent of surveyed patients with RA were open to both SQ administered at home and IV biologic therapy administered by a healthcare professional if suggested by their rheumatologist; whereas prescribers believed only 41 percent of patients were open to considering both forms of biologic therapy. Among all surveyed patients, 16 percent were open only to SQ, 14 percent were open only to IV and 16 percent were open to neither. However, surveyed prescribers believed that 34 percent were open only to SQ, 13 percent were open only to IV and 12 percent were open to neither. When asked about preference for SQ vs. IV administration overall, 28 percent of patients reported that they prefer IV therapy given by a healthcare professional, while prescribers believed only 16 percent of patients prefer IV. Twenty two percent of patients reported no preference, while 49 percent preferred SQ self-injection given at home. Prescribers believed that 31 percent of patients had no preference, and that 52 percent preferred SQ. Patient openness to and preference for SQ versus IV administration was further influenced by frequency of administration, time to complete an infusion and site of care.

“These data show that rheumatologists are well positioned to guide the shared decision making process with patients to ensure that patients are provided with information about all appropriate biologic therapy options with different routes of administration, and that patient preferences are considered,” said Susan Bolge, Ph.D., Director of Health Economics & Outcomes Research at Janssen Scientific Affairs.

About the Study
Data were collected online from both patients and prescribers through self-administered questionnaires. Patients were U.S. adults (aged ≥18), diagnosed with RA, currently treated by a rheumatologist with disease-modifying antirheumatic drugs (DMARDs), and with no history of biologic use but had discussed biologics with their physician. Prescribers were board-certified rheumatologists, practicing for 2-25 years, spent ≥50% of their time in a clinical setting seeing ≥50 RA patients per month, and were not government employees or employed by or consultants to pharmaceutical companies. A total of 243 patients were recruited through the patient advocacy organization CreakyJoints (n=101) and a consumer panel (n=142); 103 prescribers were recruited through a physician panel. 

 photo signature_zps3cc3c1d5.png

No comments:

Post a Comment

Thanks for stopping by! I appreciate all of your comments. I try to answer all of them. Sometimes life takes over and I can't get to it right away. Please don't be offended. I would love for you to leave your blog address or social media links so I can follow you or contact you. Thanks again for taking the time to be a part of my life, you are awesome!